ESTRO 2024 - Abstract Book

S2510

Clinical - Urology

ESTRO 2024

2.

E. Todio, J. Sharp, A. Morrow, N. Taylor, P. Schofield, and C. Mazariego, “Examining the effectiveness and implementation of patient treatment decision- aid tools for men with localised prostate cancer: A systematic review,” Psychooncology., 2023.

3.

C. O’Callaghan et al., “‘What is this active surveillance thing?’ Men’s and partners’ reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option,” Psycho -oncology., vol. 23, no. 12, pp. 1391 – 1398, 2014, doi: 10.1002/pon.3576.

4.

P. D. Violette et al., “Decision aids for localized prostate cancer treatment choice: Systematic review and meta analysis,” CA. Cancer J. Clin., vol. 65, no. 3, pp. 239– 251, 2015, doi: 10.3322/caac.21272.

2324

Poster Discussion

Is the biopsy still necessary for salvage treatment of recurrent prostate cancer after radiotherapy?

Wojciech Maria Burchardt 1,2 , Adam Kluska 1 , Artur Jan Chyrek 1,2 , Grzegorz Bieleda 3,2 , Ewa Burchardt 1,2 , Anna Lewandowska 4 , Adam Chichel 1,2 1 Greater Poland Cancer Centre, Brachytherapy Department, Poznan, Poland. 2 University of Medical Sciences,, Electroradiology Department,, Poznan, Poland. 3 Greater Poland Cancer Centre, Medical Physics, Poznan, Poland. 4 Greater Poland Cancer Centre, Pathology Department, Poznan, Poland

Purpose/Objective:

Dealing with local prostate cancer recurrences after radiotherapy (RT) is challenging for the oncological community. However, modern imaging modalities can localize the recurrence with high precision, which could enable less toxic focal treatment. This study analyses the effectiveness of imaging modalities in detecting the dominant recurrence of the intraprostatic lesion (DIL) after RT.

Material/Methods:

Forty-six patients with prostate cancer with a median age of 71 (range 59-82) were diagnosed with biochemical recurrences after previous radical radiotherapy (from 2008 to 2020). The median time to biochemical recurrence was 66 months (range 24-71), and the median PSA doubling time was 11,1 months (2,5-100). 44 (93,6%) patients had magnetic resonance (MR) before biopsy. 19 (40,4%) had positron emission tomography (PET) with PSMA and 25